Wave Life Sci Ord Sh (WVE) Stock Price, Quote & News

Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 ant...

Industry: Biotechnology

Sector: Healthcare

Phone: 65 6236 3388

Website: wavelifesciences.com

Address:

Marina One East Tower, 7 Straits View No.12-00, Singapore, Singapore

B_B_ Feb. 3 at 9:13 PM

$WVE Wave Life Sciences participates in a conference call with Cantor TheFly Feb 03, 2026, 09:35 PM Analyst Seedhouse holds a conference call with CEO Bolno on February 4 at 1 pm hosted by Cantor. https://www.tipranks.com/news/the-fly/wave-life-sciences-participates-in-a-conference-call-with-cantor-thefly?utm_source=webullapp.com&utm_medium=referral

0 · Reply

B_B_ Feb. 3 at 7:49 PM

$WVE J. Edward Moreno 3h Novo expects sales will drop in 2026 amid rising competitionOzempic maker Novo NordiskNVO $50.22 (-14.79%) expects annual sales to decline by up to 13% in 2026 despite signs that its new Wegovy pill, the first oral GLP-1 to come to market, is having strong early uptake. The pharmaceutical giant gave an early look at its outlook for 2026, with complete results scheduled for Wednesday morning. The Danish drugmaker said it expects sales will fall by 5% to 13%. ... https://sherwood.news/markets/novo-expects-sales-will-drop-rising-competition/

0 · Reply

B_B_ Feb. 3 at 5:32 PM

$WVE The sun'll come out tomorrow Bet your million dollar, that tomorrow there'll be sun Just thinking about tomorrow Clears away the shorters, and the sorrow 'til there's none When I'm stuck with a day that's down and lonely I just stick out my chin, and grin, and say, oh The sun'll come out tomorrow Oh, you gotta hang on 'til tomorrow, come what may Tomorrow, tomorrow, I love NOVO, tomorrow It’s only a day away February 4 Novo Nordisk Q4 2025 results

0 · Reply

B_B_ Feb. 3 at 3:24 PM

$WVE (2/2) The drug, cataloged as PF-3944 and previously known as MET-097i, came into Pfizer’s portfolio through its eye-popping $10 billion acquisition of Metsera in November. That hefty price tag reflected the company’s determination to carve out a meaningful position in the fiercely competitive obesity medication market, where rivals have already established commanding leads. … Gastrointestinal side effects, the most common adverse reactions, were predominantly mild to moderate in severity. The trial recorded no more than one instance of severe nausea or vomiting in any dose group and zero cases of severe diarrhea. … https://rollingout.com/2026/02/03/pfizer-stock-drops-obesity-drug-results/

0 · Reply

B_B_ Feb. 3 at 3:24 PM

$WVE (1/2) Pfizer falls 4% as obesity treatment shows modest results Drugmaker beats fourth-quarter expectations but investors focus on weight-loss treatment falling short of competitors By David Kesiena Feb 03, 2026 … But the earnings triumph quickly faded into the background as investors digested new clinical data on the company’s experimental obesity treatment. The results, while statistically significant, painted a picture of a drug struggling to match the blockbuster performance of category leaders. …

0 · Reply

erevnon Feb. 3 at 3:12 PM

Canaccord Genuity maintains WAVE Life Sciences $WVE at Buy and raises the price target from $40 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

B_B_ Feb. 3 at 3:00 PM

$WVE $14 Waiting for Pfizer to recover and lift the whole sector.

0 · Reply

B_B_ Feb. 3 at 2:20 PM

$WVE (2/2) The research firm highlighted that WAVE’s decision is strategically timed to take advantage of a favorable regulatory environment, specifically referencing recent feedback received by Beam Therapeutics that validated 11 micromolar of AAT protein as a viable surrogate endpoint for accelerated approval. This regulatory precedent provides what H.C. Wainwright describes as a "read-through" and "de-risked roadmap" for WAVE’s development pathway for its AATD treatment. … https://in.investing.com/news/analyst-ratings/wave-life-sciences-stock-rating-reiterated-at-buy-by-hc-wainwright-93CH-5218168

0 · Reply

B_B_ Feb. 3 at 2:20 PM

$WVE (1/2) WAVE Life Sciences stock rating reiterated at Buy by H.C. Wainwright Analyst Ratings 03-02-202 Investing.com - H.C. Wainwright has reiterated a Buy rating on WAVE Life Sciences (NASDAQ:WVE) with a price target of $30.00. The firm’s decision follows WAVE’s strategic restructuring of its lead asset portfolio, which involved regaining 100% global rights to WVE-006 for Alpha-1 Antitrypsin Deficiency (AATD) from GSK. H.C. Wainwright noted that this move transforms WAVE into a fully integrated commercial entity, positioning the company to operate independently in bringing its treatments to market.

0 · Reply

B_B_ Feb. 3 at 2:19 PM

$WVE (2/2) Canaccord noted that GSK’s decision was not triggered by any data package, as GSK has not yet seen data from the next cohort (400mg MAD), which remains on track for the current quarter. The analyst firm increased its royalty assumptions and is now giving WAVE 100% credit for future potential revenue, versus royalty payments in the high teens previously, resulting in the higher price target. … https://www.investing.com/news/analyst-ratings/wave-life-sciences-stock-price-target-raised-to-43-from-40-at-canaccord-93CH-4481549

0 · Reply

Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path

GSK

Feb 2, 2026, 7:30 AM EST - 1 day ago

Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency

Jan 21, 2026, 12:40 PM EST - 13 days ago

MoneyShow's Best Investment Ideas For 2026: Part 9

GWW TGT TTD UFPT USAC VZ WLDN

Jan 13, 2026, 8:26 PM EST - 21 days ago

Wave Life Sciences Ltd. (WVE) Presents at 44th Annual J.P.

Jan 12, 2026, 7:30 AM EST - 22 days ago

Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio

Jan 5, 2026, 8:30 AM EST - 4 weeks ago

Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 15, 2025, 6:30 AM EST - 7 weeks ago

Why Did Wave Life Sciences Surge 147%?

Dec 9, 2025, 9:50 PM EST - 2 months ago

Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 9, 2025, 2:11 PM EST - 2 months ago

What's Going On With Wave Life Sciences Stock Tuesday?

Dec 8, 2025, 4:01 PM EST - 2 months ago

Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 8, 2025, 3:17 PM EST - 2 months ago

Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Data from INLIGHT Trial of WVE-007 for Obesity Transcript

Dec 8, 2025, 7:30 AM EST - 2 months ago

Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss

Dec 7, 2025, 4:00 PM EST - 2 months ago

Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025

Dec 5, 2025, 4:12 PM EST - 2 months ago

Wave Life Sciences: Being Realistic, There Is Still So Much To Prove

Nov 11, 2025, 11:46 AM EST - 3 months ago

These Analysts Revise Their Forecasts On Wave Life Sciences Following Q3 Results

Nov 10, 2025, 8:01 PM EST - 3 months ago

Wave Life Sciences Ltd. (WVE) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 7:30 AM EST - 3 months ago

Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 7, 2025, 8:30 AM EST - 3 months ago

Wave Life Sciences to Present at Upcoming Investor Conferences

Nov 4, 2025, 8:30 PM EST - 3 months ago

Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025

Nov 4, 2025, 8:30 AM EST - 3 months ago

Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025

Nov 1, 2025, 3:06 AM EDT - 3 months ago

Wave Life Sciences Ltd. (WVE) Spotlight on RNA Editing and RNAi: Pipeline and Clinical Advances in Oligonucleotide Therapeutics Transcript

Oct 29, 2025, 10:50 PM EDT - 3 months ago

Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Oct 29, 2025, 4:15 PM EDT - 3 months ago

Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Sep 18, 2025, 8:30 AM EDT - 4 months ago

Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences

Sep 3, 2025, 3:10 PM EDT - 5 months ago

Wave Life Sciences Ltd. (WVE) Positive RestorAATion-2 Clinical Data Update Conference Transcript

Sep 3, 2025, 1:28 PM EDT - 5 months ago

Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?

GSK

Sep 3, 2025, 7:30 AM EDT - 5 months ago

Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

Jul 30, 2025, 9:38 PM EDT - 6 months ago

Wave Life Sciences Ltd. (WVE) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 7:30 AM EDT - 6 months ago

Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 23, 2025, 8:30 AM EDT - 6 months ago

Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025

Jul 7, 2025, 5:42 PM EDT - 7 months ago

Wave Life Sciences: Upgrading Rating To Buy After Turbulent 10 Months

Jun 20, 2025, 4:01 PM EDT - 8 months ago

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions

May 29, 2025, 8:30 AM EDT - 8 months ago

Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 8 months ago

Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

May 9, 2025, 4:57 PM EDT - 9 months ago

Wave Life Sciences Ltd. (WVE) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:30 AM EDT - 9 months ago

Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 8:30 AM EDT - 9 months ago

Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

Mar 27, 2025, 3:54 PM EDT - 11 months ago

Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531

Mar 26, 2025, 10:21 AM EDT - 11 months ago

Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year

Mar 26, 2025, 7:30 AM EDT - 11 months ago

Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

Mar 4, 2025, 3:16 PM EST - 1 year ago

Wave Life Sciences Ltd. (WVE) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 7:30 AM EST - 1 year ago

Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 25, 2025, 8:30 AM EST - 1 year ago

Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025

Feb 6, 2025, 8:30 AM EST - 1 year ago

Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity

Jan 8, 2025, 1:35 AM EST - 1 year ago

Wave Life Sciences Is A Buy On Pipeline Prospects

Dec 23, 2024, 8:30 AM EST - 1 year ago

Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity

Dec 16, 2024, 8:30 AM EST - 1 year ago

Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Nov 15, 2024, 8:30 AM EST - 1 year ago

Wave Life Sciences to Present at Jefferies London Healthcare Conference

Nov 12, 2024, 12:20 PM EST - 1 year ago

Wave Life Sciences Ltd. (WVE) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 4:45 PM EDT - 1 year ago

Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs

B_B_ Feb. 3 at 9:13 PM

0 · Reply

B_B_ Feb. 3 at 7:49 PM

0 · Reply

B_B_ Feb. 3 at 5:32 PM

0 · Reply

B_B_ Feb. 3 at 3:24 PM

0 · Reply

B_B_ Feb. 3 at 3:24 PM

0 · Reply

erevnon Feb. 3 at 3:12 PM

Canaccord Genuity maintains WAVE Life Sciences $WVE at Buy and raises the price target from $40 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

B_B_ Feb. 3 at 3:00 PM

$WVE $14 Waiting for Pfizer to recover and lift the whole sector.

0 · Reply

B_B_ Feb. 3 at 2:20 PM

0 · Reply

B_B_ Feb. 3 at 2:20 PM

0 · Reply

B_B_ Feb. 3 at 2:19 PM

0 · Reply

B_B_ Feb. 3 at 2:19 PM

$WVE (1/2) WAVE Life Sciences stock price target raised to $43 from $40 at Canaccord Analyst Ratings 02/03/2026 Investing.com - Canaccord Genuity raised its price target on WAVE Life Sciences (NASDAQ:WVE) to $43.00 from $40.00 on Tuesday, while maintaining a Buy rating on the stock. … The price target increase follows WAVE’s announcement that it has regained full rights to WVE-006 from GSK. According to Canaccord, GSK’s decision to return rights was based on its focus on large-scale diseases, while WAVE can pursue smaller rare conditions. WAVE plans to move the program forward quickly on a potential accelerated approval pathway, similar to BEAM’s BEAM-302. The company expects to engage with the FDA to discuss accelerated approval based on AAT biomarkers, with regulatory feedback anticipated by mid-2026.

0 · Reply

B_B_ Feb. 3 at 2:10 PM

$WVE % Held by Institutions January 28 - 79.44% January 30 - 79.86% February 3 - 80.02% https://finance.yahoo.com/quote/WVE/key-statistics/

0 · Reply

B_B_ Feb. 3 at 1:57 PM

$WVE Merck Expects Slower Earnings Growth As It Spends on Acquisitions The healthcare company said revenue rose to $16.4 billion in the fourth quarter amid growth in its oncology business By Katherine Hamilton Feb. 3, 2026 Merck recorded higher revenue in its fourth quarter, but expects earnings growth to slow as it ramps up acquisitions. The healthcare company on Tuesday posted a profit of $2.96 billion, or $1.19 a share, in the fourth quarter, compared with $3.74 billion, or $1.48 a share, a year earlier. ... https://www.wsj.com/business/earnings/merck-expects-slower-earnings-growth-as-it-spends-on-acquisitions-bb48338f?gaa_at=eafs&gaa_n=AWEtsqc-_Or1tl-j69jUiJMKgOgqeQvEweop3qPWwZJmAWHVvlFANDLZ3eNe&gaa_ts=6981fd69&gaa_sig=usfB1BqZVrhkf6zi9PDVjt427SwQv4IUXSl_DN9-kE9h9DSeQvwtVCIGo8PMk5HvdB_tpm4vgsK5FLL4TY4TTQ%3D%3D

0 · Reply

DARKP00L Feb. 3 at 1:57 PM

$WVE 08:57 on Feb. 03 2026 Canaccord Genuity Maintains Buy on WAVE Life Sciences, Raises Price Target to $43 #tradeideas

0 · Reply

B_B_ Feb. 3 at 1:56 PM

$WVE Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial Tue, Feb 3 2026 Annika Kim Constantino Pfizer on Thursday said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. … The data offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy, which could be a major boost for Pfizer after it faced several setbacks in developing obesity drugs. It’s trying to enter a market dominated by Eli Lilly and Novo Nordisk’s weekly injections, with a strong new entrant in Novo’s daily pill. While it’s unclear how much Pfizer could cut into their market share once the shot is available, monthly dosing could offer a more convenient option for patients. … https://www.cnbc.com/2026/02/03/pfizers-monthly-obesity-injection-drove-shows-promise-in-trial.html

0 · Reply

B_B_ Feb. 3 at 1:35 PM

$WVE GSK share price nears a one-year high ahead of earnings after Wave drug handback and R&D cuts by Shan Ahmed Khan London, Feb 3, 2026 ... Several analysts interpret the Wave transaction as a further step in portfolio trimming under Miels. Joseph Schwartz of Leerink Partners suggested it “could just be a new CEO sharpening and re-directing strategy,” BioPharma Dive reports. (BioPharma Dive) Investors are eyeing Wednesday’s results for clues on shifts in R&D priorities and whether the company sets clear cost-cutting targets. Updates on cash returns and near-term product momentum will also draw attention. ... https://ts2.tech/en/gsk-share-price-nears-a-one-year-high-ahead-of-earnings-after-wave-drug-handback-and-rd-cuts/

0 · Reply

B_B_ Feb. 3 at 9:47 AM

$WVE (4/4) WVE-N531 Duchenne muscular dystrophy Unlike WVE-N531, EXOCURE seeks to permanently correct the underlying genetic defect. Ex vivo CRISPR repair and the creation of muscle stem cells for curing Duchenne muscular dystrophy Luo, Yonglun (PI)Farup, Jean (PI) This research project is funded by the Novo Nordisk Foundation. … The EXOCURE is based on ex vivo CRISPR/Cas9repair of DMD mutations in patients’ own skin cells. The D MD-corrected cells will be converted into muscle stem cells by mRNA reprogramming. These DMD-corrected muscle stem cells will be used in the future as an off-the-shelf stem cell product to restore muscle functions in DMD patients. The EXOCURE will create a personalized, safe and effective therapy to cure DMD. … Effective start/end date 01/01/2022 → 31/12/2024 https://pure.au.dk/portal/en/projects/ex-vivo-crispr-repair-and-the-creation-of-muscle-stem-cells-for-c/

0 · Reply

B_B_ Feb. 3 at 9:47 AM

$WVE (3/4) WVE-003 Huntington’s Disease The Novo Nordisk Foundation supports Huntington’s disease (HD) research, such as those at the University of Rochester and the University of Copenhagen. Glial Replacement Therapy Slows Huntington’s Disease in Adult Mice Jun. 16, 2025 … which consists of labs at the University of Rochester and the University of Copenhagen. The research was supported with funding from the Lundbeck Foundation, the Novo Nordisk Foundation … https://www.urmc.rochester.edu/news/story/glial-replacement-therapy-slows-huntingtons-disease-in-adult-mice

0 · Reply

B_B_ Feb. 3 at 9:47 AM

$WVE (2/4) WVE-006 AATD After the Korro setback, Novo Nordisk now finds itself with limited options. Korro lays off 34% of staff as lead drug disappoints and Novo Nordisk pauses pact By Nick Paul Taylor Nov 13, 2025 Korro Bio delivered a double whammy of bad news, reporting lackluster data on its lead candidate and a pause to its partnership with Novo Nordisk. ... Wave Life Sciences has a rival GalNAc-conjugated RNA editing oligonucleotide in development. Korro is pivoting its AATD program to GalNAc after levels of functional AAT fell short of expectations in a phase 1/2a trial of KRRO-110. … https://www.fiercebiotech.com/biotech/korro-lays-34-staff-lead-drug-disappoints-and-novo-nordisk-pauses-pact

0 · Reply

B_B_ Feb. 3 at 9:47 AM

$WVE (1/4) After regaining full rights to the AATD therapy, Wave Life Sciences' entire portfolio is now available to Novo Nordisk, complementing their own portfolio. I think it’s possible that an agreement between Novo Nordisk and GSK facilitated the return of these rights to Wave, allowing Novo Nordisk to capitalize on this opportunity. WVE-007 Obesity “Novo has more than 200 meetings lined up for this year’s JPM, Lange told Fierce, with an eye on picking up new drug candidates and even entire platforms.” https://stocktwits.com/B_B_/message/641764956 MONDAY, SEPTEMBER 08, 2025 Novo Nordisk and GSK Collaborate on Obesity Drug Development https://stocktwits.com/B_B_/message/642650682

0 · Reply

B_B_ Feb. 3 at 9:43 AM

$WVE Wave To Work Alone on RNA Editor as AATD Picture Becomes Clearer February 2, 2026 | Heather McKenzie After GSK’s return of Wave Life Sciences’ WVE-006 as well as the mid-stage failure of Korro Bio’s candidate, the alpha-1 antitrypsin deficiency landscape is coming into focus, with Wave and Beam Therapeutics leading the way. ... The Truist group said there is room in the AATD market for multiple victors. “Given very different modality, we think there’s room for both genome editing and RNA editing,” the analysts wrote Monday. “However, we think RNA editing may offer a more ‘drug-like’ profile,” giving it more commercial traction. ... https://www.biospace.com/wave-to-work-alone-on-rna-editor-as-aatd-picture-becomes-clearer

0 · Reply

B_B_ Feb. 3 at 8:11 AM

$WVE (2/2) Demand is rising for drugs with longer-lasting effects, those that reduce body fat without muscle loss, and those with fewer side effects for long-term use. … https://www.chosun.com/english/market-money-en/2026/02/03/35ERKAF5HZEXRPY22U2IFQ2OLQ/

0 · Reply

Market Cap	2.16B
Revenue (ttm)	108.30M
Net Income (ttm)	-97.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-89.58%
Debt to Equity Ratio	0.00

Volume	2,613,700
Avg Vol	7,812,848
Day's Range	N/A - N/A
Shares Out	167.18M
Stochastic %K	59%
Beta	-1.82
Analysts	Strong Sell
Price Target	$33.53